Shopping Cart
- Remove All
Your shopping cart is currently empty
CDK8-IN-11
🥰Excellent
Catalog No. T61742Cas No. 2839338-28-0
CDK8-IN-11 is a selective and potent CDK8 inhibitor that shows antiproliferative activity in colon cancer cell lines, inhibiting WNT/β-catenin activation and TCF family transcriptional activity, inducing G1-phase arrest in HCT-116 cells, useful for colon cancer research.
CDK8-IN-11
🥰Excellent
Catalog No. T61742Cas No. 2839338-28-0
CDK8-IN-11 is a selective and potent CDK8 inhibitor that shows antiproliferative activity in colon cancer cell lines, inhibiting WNT/β-catenin activation and TCF family transcriptional activity, inducing G1-phase arrest in HCT-116 cells, useful for colon cancer research.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $92 | In Stock | |
| 5 mg | $219 | In Stock | |
| 10 mg | $323 | In Stock | |
| 25 mg | $547 | In Stock | |
| 50 mg | $788 | In Stock | |
| 100 mg | $1,110 | In Stock | |
| 200 mg | $1,490 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CDK8-IN-11"
CHIR-99021
Cited
Laduviglusib, CT99021, CHIR-99021
T2310252917-06-9
CHIR-99021 (CT99021) is an activator of the Wnt/β-catenin signaling pathway and a GSK-3α/β inhibitor (IC50=10/6.7 nM) with selective and oral activity.CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.
- $36
Size
QTY
CitedPalbociclib monohydrochloride
PD 0332991 hydrochloride, Palbociclib hydrochloride, Palbociclib (PD-0332991) HCl
T6239827022-32-2
Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.
- $30
Size
QTY
CASIN
Pirl1-related Compound 2
T3971425399-05-9
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
- $32
Size
QTY
Abemaciclib methanesulfonate Cited
LY2835219 mesylate, LY2835219 (methanesulfonate), LY2835219, abemaciclib mesylate
T31111231930-82-7
Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).
- $30
Size
QTY
CitedWnt pathway activator 1
T172561360540-81-3
Wnt pathway activator 1 is a potent Wnt activator with an IC50 of 28-29 nM. Wnt pathway activator 1 is a potent Wnt activator for the treatment of androgenetic alopecia (AGA).
- $29
Size
QTY
XAV-939 Cited
XAV939, NVP-XAV939
T1878284028-89-3
XAV-939 (NVP-XAV939) is a Tankyrase (TNKS) inhibitor that inhibits TNKS1 and TNKS2 (IC50=11/4 nM). XAV-939 selectively inhibits Wnt/β-catenin-mediated transcription.
- $48
Size
QTY
CitedRibociclib Cited
LEE011
T61991211441-98-3
Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50:10/39 nM).
- $36
Size
QTY
CitedPalbociclib Cited
PD 0332991
T1785571190-30-2
Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.
- $48
Size
QTY
CitedAbemaciclib Cited
LY2835219, CDK4/6 dual inhibitor
T23811231929-97-7
Abemaciclib (LY2835219) is a dual inhibitor of CDK4/6 (IC50=2/10 nM) with selectivity and specificity. Abemaciclib has antitumor activity and is used to treat advanced or metastatic breast cancer.
- $48
Size
QTY
CitedDinaciclib Cited
SCH 727965, PS-095760
T1912779353-01-4
Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.
- $47
Size
QTY
CitedUrea
Ureophil, E-Cardamoni, Carbonyldiamide, Carbamide
T073857-13-6
Urea (Carbonyldiamide) is formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end metabolite of protein catabolism and accounts for about one-half of the total urinary solids.
- $30
Size
QTY
Nefopam hydrochloride
Nefopam HCl, Fenazoxine hydrochloride
T047023327-57-3
Nefopam hydrochloride (Nefopam HCl) is the hydrochloride salt form of nefopam, a centrally-acting, non-opioid benzoxazocine with analgesic activity.
- $37
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | CDK8-IN-11 is a selective and potent CDK8 inhibitor that shows antiproliferative activity in colon cancer cell lines, inhibiting WNT/β-catenin activation and TCF family transcriptional activity, inducing G1-phase arrest in HCT-116 cells, useful for colon cancer research. |
| Targets&IC50 | CDK8:46 nM |
| In vitro | Cdk8-in-11 has a strong selective inhibitory activity against CDK8 with IC50 of 46 nM. CDK8-IN-11 (0-50 μM, 48 h) inhibited the proliferation of HCT-116, HHT-29, SW480, CT-26 and GES-1 cells with IC50 values of 1.2, 0.7, 2.4, 5.5 and 62.7 nM, respectively. [1] |
| In vivo | In CT-26 xenografted mouse models, CDK8-IN-11 (10 and 40 mg/kg, p.o) inhibited tumor growth. [1] |
| Molecular Weight | 388.34 |
| Formula | C19H15F3N4O2 |
| Cas No. | 2839338-28-0 |
| Smiles | O=C(NC1=CC=C(OC2=CN=C(N)C=C2)C=C1)NC3=CC=CC(=C3)C(F)(F)F |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 200 mg/mL (515.01 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CDK8-IN-11 | purchase CDK8-IN-11 | CDK8-IN-11 cost | order CDK8-IN-11 | CDK8-IN-11 chemical structure | CDK8-IN-11 in vivo | CDK8-IN-11 in vitro | CDK8-IN-11 formula | CDK8-IN-11 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.